Lewis Neese, MD
Pulmonary Disease · Hattiesburg, MSNPI 1841305950
Payments from drug & device makers
Across 521 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$925
- Mylan Specialty L.p.$791
- Grifols USA, LLC$702
- Boehringer Ingelheim$547
- Viatris Specialty LLC$310
- plus $3K from 33 others
What the payments were for
- Food & beverage$8,568100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 180 | $2,366 |
| AstraZeneca | 48 | $925 |
| Mylan Specialty L.p. | 43 | $791 |
| Grifols USA, LLC | 39 | $702 |
| Boehringer Ingelheim | 32 | $547 |
| Viatris Specialty LLC | 23 | $310 |
| United Therapeutics Corporation | 11 | $251 |
| Mallinckrodt Hospital Products Inc. | 11 | $217 |
| Electromed, Inc. | 19 | $199 |
| Actelion Pharmaceuticals US, Inc. | 9 | $180 |
| Regeneron Healthcare Solutions, Inc. | 8 | $173 |
| Sanofi | 8 | $173 |
| Merck | 7 | $133 |
| Baxter Healthcare | 5 | $129 |
| Sunovion Pharmaceuticals Inc. | 6 | $120 |
| Axsome Therapeutics, Inc. | 4 | $119 |
| Shionogi Inc | 7 | $118 |
| Amgen | 5 | $110 |
| Bayer | 7 | $108 |
| ANI Pharmaceuticals, Inc. | 5 | $107 |
| Jazz Pharmaceuticals Inc. | 5 | $103 |
| Novartis | 5 | $85 |
| Insmed, Inc. | 5 | $73 |
| Genentech USA, Inc. | 4 | $73 |
| Pfizer | 5 | $72 |
| Johnson & Johnson | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Philips North America LLC | 2 | $42 |
| Inari Medical, Inc. | 3 | $41 |
| Pulmonx Corporation | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Octapharma USA, Inc. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $22 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| AbbVie | 1 | $18 |
| Harmony Biosciences LLC | 1 | $15 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
How this compares
$8,568 in reported general payments places this provider in the 60th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $307,487 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 302 | $240,062 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $91,075 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 147 | $82,214 |
| Spiriva RespimatTiotropium Bromide | 91 | $61,149 |
| Breo ElliptaFluticasone/Vilanterol | 131 | $58,214 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 115 | $56,266 |
| Incruse ElliptaUmeclidinium Bromide | 79 | $26,054 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $20,212 |
| Arnuity ElliptaFluticasone Furoate | 71 | $18,070 |
| XareltoRivaroxaban | 24 | $13,911 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 66 | $13,306 |
| EliquisApixaban | 17 | $12,936 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 328 | $11,514 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $7,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $547 | $450,849264 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,366 | $398,666698 claims |
| Grifols USA, LLCProlastin C | $702 | $91,07512 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $925 | $27,84464 claims |
| Johnson & JohnsonXarelto | $49 | $13,91124 claims |
| PfizerEliquis | $72 | $12,93617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Hattiesburg
- L AldredHattiesburg$76K
- Walid YounisHattiesburg$15K
- Tamer HudaliHattiesburg$15K
- Michael RaggioHattiesburg$11K
- Kevin KinlochHattiesburg$6K
- Randolph RossHattiesburg$5K
- Charles McCollumHattiesburg$4K
- Andrew RognessHattiesburg$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.